CompletedNCT02477280
Methylphenidate for ADHD
It tested methylphenidate for ADHD.
Addiction, ADHDDrugFrom 18 Years to 60 Years
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Västerås, SwedenSee all locations and recruitment
Compensation and expense reimbursement have not been verified for this summary.
Study information
Study start dateSeptember 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 39
- Sponsor
- Region Västmanland
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Sweden
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT02477280
- Official title
- Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder
Recruitment & locations
CompletedVästerås
Questions about this study
Who is behind this study?
The study sponsor is Region Västmanland.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2019-000737-39
A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Tolerability of AD04 (Ondansetron) in Adults with A...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedEUCTR 2010-021533-31
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedEUCTR 2011-000210-19
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.